Medvi, a telehealth startup operating with just two employees, is projecting $1.8 billion in sales this year after generating $65 million in profit on $401 million in revenue last year. The company’s meteoric rise is a case study in the aggressive convergence of generative AI and affiliate marketing, but it has likewise landed the firm in the crosshairs of the FDA, the FTC, and multiple lawsuits. The central tension is clear: Medvi has scaled a massive healthcare enterprise with minimal overhead, but that speed may have come at the cost of fundamental regulatory compliance and medical integrity.
The AI-Driven Acquisition Engine
Founder Matthew Gallagher’s approach to building Medvi was an exercise in extreme lean operations. In the company’s first month, Gallagher spent $20,000 on marketing and a suite of AI tools—including ChatGPT, Claude, and Grok—to build the infrastructure, populate the site with copy, and manage customer interactions. While the company now employs human professionals for legal and accounting needs, the core of the business remains an automated machine.
The growth strategy relies heavily on affiliate marketers, who Gallagher estimates account for roughly 30% of the company’s advertising. Although, this decentralized marketing model has led to a proliferation of deceptive content. Meta’s ad library recently revealed thousands of active campaigns linking to Medvi, some featuring AI-generated “doctors” with garbled text in their photos or profiles that were previously used by gospel musicians and clothing stores in the Republic of Congo.
One particularly egregious example involved a profile for a “Dr. Amelia Rhodes,” which used an image of Johns Hopkins Hospital. No such physician exists in the Maryland Board of Physicians database or within the Johns Hopkins system. When these discrepancies were brought to light, the number of active ads plummeted from over 5,000 to roughly 2,800, suggesting a reactive rather than proactive approach to quality control.
Regulatory Friction and the “Whack-a-Mole” Problem
The FDA has already issued a warning letter to Medvi, stating that representations on one of its associated sites were “false or misleading,” specifically regarding comparisons to FDA-approved drugs like Wegovy and claims about the compounding of the drugs sold. Gallagher defended the company by claiming the site in question was operated by an unauthorized affiliate who used the company name without permission.

This defense highlights a systemic issue in the modern telehealth landscape. The National Consumers League has requested an FTC investigation into Medvi and five other telehealth firms, arguing that the use of “doctor-approved” labels on compounded drugs confuses consumers about safety and testing. For regulators, policing these entities is described as a game of “whack-a-mole,” as companies can quickly pivot domains or shift blame to third-party affiliates.
The legal pressure is mounting beyond regulatory warnings. Medvi is currently facing multiple lawsuits alleging violations of spam laws via unsolicited texts and emails. While the company denies any illegal conduct, the pattern of aggressive, AI-enhanced outreach is placing it in a precarious position with the FTC, which requires advertisers to maintain “reasonable programs” to oversee affiliates—especially in high-risk sectors like healthcare.
A Pattern of Volatility in Digital Health
Medvi is not an isolated incident but rather a symptom of a broader, volatile trend in the post-pandemic telehealth boom. The surge in demand for GLP-1 weight-loss medications and ADHD treatments has created a gold-rush environment where speed often supersedes safety.
- Cerebral: Paid millions to resolve a federal investigation into overprescribing and faced FTC scrutiny over deceptive billing.
- Done: Its founder was found guilty of healthcare fraud conspiracy related to the distribution of controlled substances.
The commercial stakes are high. While the percentage of doctors seeing patients virtually remains triple pre-pandemic levels, the industry is shifting. The transition from “growth at all costs” to a regulated environment means that companies like Medvi, which rely on AI-generated facades and loosely managed affiliates, may find their margins eroded by legal fees and regulatory sanctions.
How does Medvi’s business model differ from traditional telehealth?
Traditional telehealth typically focuses on bridging the gap between a licensed physician and a patient. Medvi operates more as a high-efficiency marketing funnel, using AI to minimize operational overhead and affiliate networks to maximize reach, effectively treating healthcare prescriptions as a scalable e-commerce product.
What is the specific risk regarding “compounded drugs”?
Compounded drugs are customized versions of medications. The risk arises when telehealth companies market these as equivalents to FDA-approved brand-name drugs (like Wegovy) without the same rigorous safety testing and standardization, potentially misleading consumers about the drug’s efficacy and safety.
What are the likely legal consequences for failing to monitor affiliates?
Under the FTC Act, companies can be held liable for deceptive claims made by their affiliates if they fail to implement “reasonable programs” for oversight. This could result in significant fines, mandated refunds to consumers, and court-ordered changes to their marketing operations.
As AI continues to lower the cost of creating professional-looking medical personas, will regulators be able to keep pace with the speed of synthetic deception in healthcare?




